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Abstract
Background: This retrospective cohort study aimed to investigate whether simple routine blood tests at presentation
(C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), alkaline phosphatase and albumin) predict survival in patients
with osteosarcoma. Methods: Between January 1998 and February 2015, 134 patients with a histological diagnosis of
osteosarcoma were treated in our unit. Of these, 79 patients with high-grade osteosarcomas were included in the study.
Demographic and clinical data, and laboratory parameters obtained prior to biopsy (CRP, ESR, alkaline phosphatase and
albumin levels), were obtained from patients’ records. Results: There were 44 males and 35 females. Univariate analysis
showed that high pre-biopsy CRP (p ¼ 0.004), raised pre-biopsy ESR (p ¼ 0.010), older age (p < 0.001), poor tumour
necrosis rates (90%, p ¼ 0.023) and metastasis at presentation (p < 0.001) were poor prognostic factors. Multivariate
analysis showed pre-biopsy CRP and ESR levels to be independent predictors of overall survival (p¼ 0.020 and p¼ 0.025,
respectively). Kaplan–Meier survival was significantly lower in patients with elevated CRP (p¼ 0.002) and ESR (p¼ 0.003).
Hypoalbuminaemia and elevated alkaline phosphatase levels did not correlate with overall survival. Conclusion: Pre-
operative CRP and ESR levels may have value in building a prognostic model for patients presenting with osteosarcoma.
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Background
Osteosarcoma is the most common primary malignant bone
tumour.1,2 Accurate staging is important to guide therapy,
and in recent years, there has been an emphasis on devel-
oping and identifying new biomarkers associated with
treatment response and prognosis. Many of these proposed
biomarkers are novel and include, for example, microRNA
evaluation.3–5 However, it is clear that some existing rou-
tine diagnostic blood tests may have value as biomarkers,
including C-reactive protein (CRP), erythrocyte sedimenta-
tion rate (ESR), alkaline phosphatase and albumin; the
measurement of which is simple, rapid, and cost-effective.
CRP is an acute phase protein, which is predominantly
produced by hepatocytes. A high-serum CRP level is an
indicator of a poorer prognosis in many cancers, including
breast cancer, colorectal cancer and gastrointestinal
cancer.6–8 Patients with other diseases such as type 2 dia-
betes, cardiovascular disease and arthritis may develop
high CRP levels.9–11 Both tumour growth and host response
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to tumour growth can result in tissue inflammation, leading
to an elevated CRP.
ESR is a classic inflammatory marker that constitutes
one of the oldest laboratory measurements. ESR can often
be elevated in cases of infection, malignancy and autoim-
mune disease.12–14 It also has clinical significance in the
follow-up and prognosis of noninflammatory conditions
such as prostate cancer15 and coronary artery disease.16
Alkaline phosphatase is primarily secreted by the liver and
the bone, although a small amount is also secreted by intes-
tine, kidneys and leukocytes.17 Serum alkaline phosphatase
level is usually greater in children than in adults18 due to
osteoblast activity at the growth plates. It can therefore be
considered to have some disease specificity in the context
of osteosarcoma.
Increased albumin degradation rates have been docu-
mented in patients with chronic inflammation.19 Hypoalbu-
minaemia has been reported to have prognostic value in
prostate cancer.20 Tumour necrosis factor (TNF) and inter-
leukin 6 (IL-6) are known to downregulate albumin synth-
esis and increase acute-phase protein production in
hepatocytes.21
This retrospective cohort study aimed to investigate
whether routine blood tests (CRP, ESR, alkaline phos-
phatase and albumin) predicted overall survival in
patients with osteosarcoma (Figures 1, 2, 3, 4). We
wanted to evaluate whether these tests could serve as
useful benchmarks with which to compare novel
disease-specific biomarkers and whether they should
be included in a prognostic model.
Methods
Study design and patients
Between January 1998 and February 2015, 134 patients
with a histological diagnosis of an osteosarcoma were
treated at our centre. Demographic data including age, sex,
tumour site, stage, grade, metastases at presentation and the
results of blood tests prior to any therapy were obtained
from clinical records. The tumour necrosis rate after che-
motherapy was defined as poor if 90% or good if >90%
on histological assessment.
Patients were excluded from this retrospective cohort
study because of incomplete clinical data in 37 cases
and 18 cases with low or unknown grade of osteosar-
coma. All 79 patients had an alkaline phosphatase level
available. Albumin was unavailable for 1 patient, CRP
was unavailable for 9 patients and ESR was unavailable
for 39 patients.
Overall survival was the primary endpoint in this
study; this was defined as the period from diagnosis to
death. Patients were treated within a multidisciplinary
team according to best practice at the time of presenta-
tion, in recent years as per the British Sarcoma Group
guidelines.22
Blood tests
CRP, alkaline phosphatase and albumin assays pre-biopsy
were measured as part of a routine biochemical examina-
tion. During the period of the study, the biochemistry
laboratory used different machines: Olympus AU, Roche
Modular P and Roche Cobas c702 autoanalyser, which was
introduced in 2010. While there would be slight variation in
measurement accuracy this would not be at a level that
would affect the overall results. The following methods
were used for the respective analytes, serum albumin: spec-
trophotometric method using bromocresol green, serum
ALP: spectrophotometric method using p-nitrophenyl
phosphate and serum CRP: particle-enhanced immunotur-
bidimetric assay. A high-serum CRP level was defined as
>5 mg/L, high alkaline phosphatase was taken as >110 U/L
in adults and >150 U/L in children, low albumin as
<40 g/L. ESR was measured using the Starrsed RL analy-
ser, a high ESR was defined as >22 mm/h in males and
>29 mm/h in females.
Statistical analysis
Analyses were performed to assess the relationships
between CRP, ESR, alkaline phosphatase and albumin lev-
els, baseline clinical factors, tumour necrosis rates and
overall survival of the patients. Kaplan–Meier survival
curves were used to estimate the overall survival in patients
grouped according to high or low values of CRP, ESR,
alkaline phosphatase and albumin at presentation. The
log-rank test was used to compare overall survival of the
patients. A multivariate analysis was performed using a
Cox proportional hazard model with significant blood tests
identified in the univariate analysis as variables. A value of
p < 0.05 was considered to be significant in all statistical
analyses. Calculations were made using IBM SPSS Statis-
tics for Windows, version 24, 2016 (IBM Corp., Armonk,
New York, USA).
Results
The demographic details are given in Table 1. The mean
follow-up was 45 months (1–172). The primary sites for
tumour were the extremity in 64 cases, pelvis in 1 case,
spine in 4 cases, head in 6 cases and trunk in 4 cases.
Discussion
We investigated the role of routine blood tests in predicting
clinical outcomes in patients with high-grade osteosarcoma
(Table 2). Our finding of an association between an ele-
vated CRP and worse overall survival is consistent with
previous observations in many other malignancies.
Immune cells responding to inflammation produce cyto-
kines, particularly IL-6, which in turn induces transcription
and subsequent production of CRP from hepatocytes.23–25
In patients with osteosarcoma, Nakamura et al.26 reported
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that an elevated CRP was an adverse prognostic factor for
local tumour control but did not affect the disease-specific
survival. However, they found that a raised CRP was an
adverse prognostic factor for disease-specific survival in
chondrosarcoma and Ewing’s sarcoma. Our data corrobo-
rate with Funovics et al.27 who showed that in patients with
high-grade osteosarcoma, preoperative CRP levels, that is,
after biopsy but before tumour resection correlate with
disease-specific outcome. Our patients had blood tests prior
to biopsy, and therefore there were no confounding vari-
ables relating to prior invasive procedures.
Alkaline phosphatase can be regarded as a marker of
bone turnover. A meta-analysis by Ren et al. concluded
that a high-serum alkaline phosphatase level is associated
with poor overall survival in osteosarcoma patients.28 Cul-
tured human osteosarcoma cell lines29,30 have been shown
to produce large amount of alkaline phosphatase, and
serum levels have been shown to be significantly elevated
in patients with osteoblastic osteosarcoma subtypes.31
There are reports of patients presenting with an initial
raised serum alkaline phosphatase that return to normal
levels after preoperative chemotherapy,32 however in an
Table 1. Baseline patient characteristics.
Variable
Patients (n) 79
Mean age in years 27 (range 4–87)
Sex 44 males, 35 females
Tumour site
Extremity 64
Pelvis 1
Spine 4
Trunk 4
Head 6
Stage (metastases at presentation lung
or bone or both)
No 63
Yes 14
Information not available 2
Tumour necrosis rates
Good >90% 17
Poor 90% 38
Descriptions only (no percentage
stated in the report)
24
Table 2. Univariate analysis of prognostic factors for overall
survival.a
Variable
Overall survival
Hazard ratio
(95% CI)
p
Valueb
Sex 1.652 (0.800–3.414) 0.175
Age (<40 vs. 40 years) 0.185 (0.082–0.415) <0.001
Tumour necrosis (good >90% vs.
poor 90%)
0.538 (0.315–0.919) 0.023
Metastasis at presentation 4.070 (1.904–8.701) <0.001
Pre-biopsy CRP level 3.338 (1.466–7.603) 0.004
Pre-biopsy ESR level 6.378 (1.561–26.050) 0.010
Pre-biopsy albumin level 0.740 (0.282–1.943) 0.541
Pre-biopsy alkaline phosphatase
level
1.487 (0.567–3.899) 0.420
CI: confidence interval; CRP: C-reactive protein; ESR: erythrocyte sedi-
mentation rate.
aUnivariate analysis showed that blood tests results at presentation with
high CRP (p ¼ 0.004), raised ESR (p ¼ 0.010), older age (p < 0.001),
poor tumour necrosis rate (p ¼ 0.023) and metastasis at presentation
(p < 0.001) were all poor prognostic factors for overall survival.
bCox regression model.
Table 3. Multivariate analysis for prognostic factors for survival.a
Factor
Hazard ratio
(95% CI) p Valueb
CRP
>5 mg/L 5.95 (1.33–26.66) 0.020
5 mg/L 1
ESR
High ESR (22 mm/h in males,
29 mm/h in females)
5.52 (1.24–24.53) 0.025
Low ESR (<22 mm/h in males,
<29 mm/h in females)
1
Tumour necrosis
poor 90% 1.42 (0.50–4.04) 0.514
good >90% 1
CI: confidence interval; CRP: C-reactive protein; ESR: erythrocyte sedi-
mentation rate; HR: hazard ratio.
aMultivariate analysis showed pre-biopsy CRP and ESR levels to be inde-
pendent predictors of worse overall survival HR 5.95 95% CI (1.33–
26.66), p ¼ 0.020 and HR 5.52 95% CI (1.24–24.53), p ¼ 0.025,
respectively.
bCox proportional hazard model.
Figure 1. Kaplan–Meier curve for overall survival of patients with
osteosarcoma according to serum CRP levels. High CRP taken
as over 5 mg/mL correlates with decreased survival (p ¼ 0.002),
n ¼ 70. CRP: C-reactive protein.
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international multicentre study involving 2680 patients
with osteosarcoma, Pakos et al.33 reported that serum alka-
line phosphatase was not a prognostic factor in terms of
disease outcome. Likewise, raised alkaline phosphatase
levels did not correlate with overall survival in our study
and this may be due to the wide range of values that are
produced when alkaline phosphatase is measured.
Regarding clinical factors, metastases at presentation,
age,34,35 tumour location,33 size36 and chemotherapy-induced
necrosis33 have been reported as important prognostic
factors in osteosarcoma. We found older age (>40 years)
to be an adverse prognostic factor, while tumour necrosis
was significant in the univariate analysis but not the
multivariate. Some studies have also not clearly demon-
strated the correlation of tumour necrosis with survival in
osteosarcoma patients.37,38 Kim et al.39 reported that
tumour necrosis rate adjusted by tumour volume change
was a better predictor of survival in osteosarcoma
Figure 2. Kaplan–Meier curve for overall survival of patients with
osteosarcoma according to ESR levels. High ESR correlates with
decreased survival (p ¼ 0.003), n ¼ 40. ESR: erythrocyte sedi-
mentation rate.
Figure 3. Kaplan–Meier curve for overall survival of patients with
osteosarcoma according to serum alkaline phosphatase levels.
There was no correlation between alkaline phosphatase levels and
survival (p ¼ 0.417), n ¼ 78.
Figure 4. Kaplan–Meier curve for overall survival of patients with
osteosarcoma according to serum albumin levels. There was no
correlation of albumin with survival (p ¼ 0.539), n ¼ 79.
Figure 5. Kaplan–Meier curve for overall survival of patients with
osteosarcoma. The estimated 1-, 5- and 10-year overall survival
was 0.802 (SE: 0.049), 0.549 (SE: 0.069) and 0.474 (SE: 0.078),
respectively, n ¼ 79. SE: standard error.
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patients. In our series, CRP and ESR have out-performed
tumour necrosis rate in the multivariate analysis indicat-
ing that they are useful to document as an indicator
of prognosis (Table 3).
Research into circulating disease-specific biomarkers
for osteosarcoma has increased markedly in recent years.
MicroRNAs in particular3–5 have received attention and
there are ongoing studies assessing circulating free tumour
DNA and intact circulating tumour cells. The attraction of
these novel biomarkers is not only the potential for correla-
tion with clinical outcomes but also the potential to indicate
additional therapeutic options for the patient. However, to
date none of these newer biomarkers have made it into the
clinical arena. It is important therefore that groups
researching novel biomarkers compare the performance
with readily available laboratory values such as CRP and
ESR in terms of correlation with clinical outcomes. More-
over, the development of algorithms which include all of
these markers is proving effective in other solid cancers.40
The strength of our study is that CRP and ESR remain
useful markers despite the heterogeneity of our study pop-
ulation of osteosarcoma patients which has included a wide
age range and various pathological subtypes. There are
limitations of our study including its retrospective design
and a small sample size from a single-centre experience.
We did not consider the presence of other systemic condi-
tions that could be associated with raised inflammatory
markers. We did not have a sufficient number of patients
to allow further risk stratification. We reported on the over-
all survival (Figure 5) rather than disease-specific survival
because we did not have a specific cause of death.
Conclusion
Elevated serum CRP and ESR are associated with worse
overall survival in this group of osteosarcoma patients. We
recommend the use of these routine blood markers to help
identify patients at higher risk of mortality and to use as a
benchmark to compare the novel disease-specific biomar-
kers currently being extensively investigated.
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